Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

328.97 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
Amgen (AMGN) Q2 Profit Jumps 21% ↗
Via The Motley Fool
News headline image
Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue... 
Via StockStory
News headline image
Amgen Inc (NASDAQ:AMGN) Surpasses Q2 2025 Earnings Estimates Despite Muted Market Reaction ↗
Amgen beats Q2 2025 earnings with $9.179B revenue and $6.02 EPS, but shares dip slightly as market reaction remains muted. CEO highlights growth in biosimilars and raised full-year guidance. 
Via Chartmill
News headline image
Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News? ↗
Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout. 
Via Investor's Business Daily
News headline image
Stock Market Today: US Stock Futures Inch Higher, As Analysts Warn of Volatile August—AMD, Pfizer, Caterpillar In Focus ↗
U.S. stock futures are inching higher on Tuesday, following a strong rally on Monday, with major benchmark indices in the green. 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Uncovering Potential: Amgen's Earnings Preview ↗
 
Via Benzinga
News headline image
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday? ↗
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
News headline image
Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
What Analysts Are Saying About Amgen Stock ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Amgen ↗
 
Via Benzinga
News headline image
What Does the Market Think About Amgen? ↗
 
Via Benzinga
News headline image
Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics ↗
 
Via Benzinga
Topics Economy Government
News headline image
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial ↗
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast. 
Via Benzinga
News headline image
2 Top Dividend Stocks to Buy Right Now and Hold Forever ↗
Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate ↗
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
News headline image
2 Reasons to Like AMGN and 1 to Stay Skeptical
Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up... 
Via StockStory
Topics Government Stocks
News headline image
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
How Does Nvidia's Reaching $4 Trillion in Market Cap Impact the S&P 500, Nasdaq-100, and Dow Jones? ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
News headline image
An Investor Wonders Why Trump's Tariffs Aren't Shaking The Markets. 'Does Wall Street Simply Not Care About The Economy Anymore?' ↗
 
Via Benzinga
Topics Economy Government
News headline image
This House of Representative Just Bought Up To $30K In Amgen Stock ↗
 
Via Benzinga
News headline image
1 Top Dividend Growth Stock to Buy Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Dividend ETF to Buy for Passive Income: SCHD or GCOW ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades' ↗
Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets. 
Via Benzinga
News headline image
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.